Note: Apurba Shastry's textbook is not in the library database, but I've used the three standard medical microbiology textbooks available - Jawetz, Melnick & Adelberg's Medical Microbiology (28e), Medical Microbiology 9e (Murray), and Sherris & Ryan's Medical Microbiology (8e) - which cover the same curriculum content. The information below aligns with standard 2nd year MBBS microbiology syllabus as covered in Apurba Shastry's style.

🦠 COVID-19 (SARS-CoV-2) - Complete Microbiology Summary

1. MORPHOLOGY

┌─────────────────────────────────────────────────────────┐
│              SARS-CoV-2 STRUCTURE                       │
│                                                         │
│   [Spike (S) glycoprotein] ← Crown-like projections    │
│        │                                                │
│   [Envelope (E) protein]                               │
│        │                                                │
│   [Membrane (M) protein]  ← Most abundant              │
│        │                                                │
│   [Nucleocapsid (N) protein] ← Helical, binds RNA      │
│        │                                                │
│   [+ssRNA genome] ← Largest RNA virus genome (27-32kb) │
└─────────────────────────────────────────────────────────┘

Key Structural Facts - Mnemonic: "SEMEN"

Physical Properties

💡 Mnemonic for genome: "PLUS Size RNA" = +ssRNA, Largest genome among RNA viruses

2. PATHOGENESIS

PATHOGENESIS FLOWCHART
========================

ENTRY via respiratory tract
         │
         ▼
Initial targets: Nasopharyngeal / Oropharyngeal cells
         │
         ▼
Spike protein RBD binds ACE2 receptor
         │
         ▼
Cleavage of S1/S2 by TMPRSS2 (at plasma membrane)
         and Cathepsin L (endosomal route)
         │
         ▼
Viral fusion + entry into cell
         │
         ▼
+ssRNA released in cytoplasm
         │
         ▼
Translation → Polyprotein
         │
         ▼
Cleavage by viral + host proteases
→ RdRp (RNA-dependent RNA Polymerase)
→ Structural proteins (S, E, M, N)
→ Non-structural proteins (nsp1-16 including ExoN proofreader)
         │
         ▼
Replication in airways, bronchial epithelium,
alveolar epithelial cells, vascular endothelium,
alveolar macrophages
         │
         ▼
Virus assembled in cytoplasm, enveloped
by ER-Golgi membranes, released
         │
         ▼
Innate immune evasion (viral nsps block IFN-I signals)
         │
         ├──── MILD DISEASE ────────────────────────────┐
         │     Local inflammation, clearance             │
         │                                               │
         └──── SEVERE DISEASE ──────────────────────────┘
               Cytokine Storm:
               ↑ IL-1β, IL-6, IL-8, TNF-α
               ↑ Recruitment of T cells, monocytes, neutrophils
               ↑ Pulmonary edema → Hyaline membrane formation
               → ARDS, DIC, Multi-organ failure

ACE2 Expression & Organ Vulnerability

         ACE2 is expressed in:
         ┌──────────────────────┐
         │  Lungs (type II      │ ← Primary target
         │  pneumocytes)        │
         │  Heart (myocardium)  │
         │  Kidneys (tubular)   │
         │  Liver               │
         │  Gut (enterocytes)   │
         │  Blood vessels       │
         └──────────────────────┘
         → Multi-organ involvement in severe disease

Immune Response

Variants - Mnemonic: "A Big Pilot Dives" (Alpha, Beta, Gamma/P.1, Delta)

All have increased ACE2 binding affinity → higher transmissibility and pathogenicity

3. CLINICAL MANIFESTATIONS

CLINICAL SPECTRUM FLOWCHART
==============================

Exposure → Incubation: 2-14 days (median 5-6 days)
                │
                ▼
        ┌───────────────────────────────────────────────┐
        │            SYMPTOMATIC CASES                  │
        └───────────────────────────────────────────────┘
                │
        ┌───────┴────────────────────────┐
        │                                │
        ▼                                ▼
   ASYMPTOMATIC               SYMPTOMATIC (80% mild-moderate)
   (significant proportion,    Fever/Chills
    still transmit virus)       Dry cough
                                Fatigue
                                Myalgia/Body aches
                                Headache
                                Anosmia/Ageusia (~10%)
                                Sore throat
                                Nausea/Vomiting
                                Diarrhea
                                │
                                ▼
                        SEVERE (~15%):
                        Dyspnea (shortness of breath)
                        Chest pain/pressure
                        New confusion
                        Inability to wake/stay awake
                        Bluish lips/face (cyanosis)
                                │
                                ▼
                        CRITICAL (~5%):
                        Viral pneumonia
                        Acute Hypoxemic Respiratory Failure
                        ARDS
                        Septic Shock
                        Multi-organ dysfunction

Mnemonic for Symptoms - "FETCH A COLD NOSE"

Risk Factors for Severe Disease - Mnemonic: "OLD CHICK"

Complications & Sequelae

4. LABORATORY DIAGNOSIS

DIAGNOSTIC ALGORITHM
======================

Clinical Suspicion
       │
       ▼
┌──────────────────────────────────────────┐
│      SPECIMEN: Nasopharyngeal swab       │
│      (preferred) / Oropharyngeal swab    │
└──────────────────────────────────────────┘
       │
       ├────────────────────────────────────┐
       │                                    │
       ▼                                    ▼
MOLECULAR TEST                        ANTIGEN TEST
(for CURRENT infection)               (for CURRENT infection)
       │                                    │
RT-PCR (Gold Standard)              Detects viral Nucleocapsid (N)
  - Detects viral RNA                  protein
  - Highly sensitive                   - Rapid result
  - Confirms diagnosis                 - Less sensitive
  - Uses RdRp, N, E gene targets       - Positive = Confirmed
                                       - Negative → confirm by PCR
       │
       ▼
BioFire Respiratory Panel RP2.1
  - Multiplex NAT
  - Detects 15 viruses + 4 bacteria
  + SARS-CoV-2 and common cold CoVs

       │
       ▼
ANTIBODY TEST (Serological)
  - For PAST infection / epidemiology
  - NOT for acute diagnosis
  - Detects IgM, IgG against SARS-CoV-2

Summary Table

💡 Mnemonic: "RAP = RT-PCR → Antigen → Past (serology)" in order of preference for current infection

5. TREATMENT

TREATMENT APPROACH
===================

Severity Assessment
        │
        ├──── MILD-MODERATE ──────────────────────────────►
        │     • Supportive care (rest, fluids, antipyretics)
        │     • Monoclonal antibodies (high-risk patients):
        │       - Bamlanivimab
        │       - Casirivimab + Imdevimab (cocktail)
        │       (Target Spike glycoprotein; FDA Emergency Use)
        │
        ├──── SEVERE ─────────────────────────────────────►
        │     • Remdesivir (antiviral)
        │       - RdRp inhibitor → stops viral RNA synthesis
        │     • Dexamethasone (corticosteroid)
        │       - Reduces cytokine storm / inflammation
        │
        └──── CRITICAL (ICU) ─────────────────────────────►
              • ICU admission
              • Intubation + Mechanical ventilation
              • Prone positioning
              • Anticoagulation (for thrombosis)

Drug Summary Table - Mnemonic: "Red Dexa Mono"

Prevention

PREVENTION PYRAMID
===================

        ▲▲▲  Vaccination (mRNA or adenoviral vector)
       ▲▲▲▲▲  Mask wearing / Face shield
      ▲▲▲▲▲▲▲  Social distancing (>6 feet)
     ▲▲▲▲▲▲▲▲▲  Avoid crowded / poorly ventilated spaces
    ▲▲▲▲▲▲▲▲▲▲▲  Hand hygiene (soap or ≥60% alcohol sanitizer)
   ▲▲▲▲▲▲▲▲▲▲▲▲▲  Cover cough/sneeze
  ▲▲▲▲▲▲▲▲▲▲▲▲▲▲▲  Disinfect frequently touched surfaces

Vaccines

QUICK REVISION OVERVIEW

COVID-19 AT A GLANCE
======================

Virus: SARS-CoV-2 (Beta-coronavirus)
Genome: +ssRNA, 27-32 kb (largest RNA virus genome)
Structure: Enveloped, Helical nucleocapsid, 120-160 nm
Key proteins: Spike (S), Envelope (E), Membrane (M), Nucleocapsid (N)
Receptor: ACE2 (+ TMPRSS2 cleavage)
Transmission: Droplets > Aerosol > Fomites
Incubation: 2-14 days (median 5-6 days)
Diagnosis Gold Standard: RT-PCR (nasal/pharyngeal swab)
Treatment: Remdesivir + Dexamethasone (severe)
           Monoclonal Ab (high-risk mild-moderate)
Prevention: Vaccination + Masks + Hand hygiene

Sources: Sherris & Ryan's Medical Microbiology, 8th Edition (Sherris); Jawetz, Melnick & Adelberg's Medical Microbiology, 28th Edition (Jawetz); Medical Microbiology 9e (Murray). The Apurba Shastry textbook is not available in the current library but this content covers the identical MBBS curriculum topics. The major facts (morphology, ACE2 pathogenesis, RT-PCR diagnosis, Remdesivir/Dexamethasone treatment) are consistent across all standard microbiology texts used in Indian medical education.